Informace o projektu
MEDGENET - Medical genomics and epigenomics network
(MEDGENET)
- Kód projektu
- 692298
- Období řešení
- 1/2016 - 12/2018
- Investor / Programový rámec / typ projektu
-
Evropská unie
- Horizon 2020
- Spreading excellence and widening participation
- Fakulta / Pracoviště MU
- Středoevropský technologický institut
- Spolupracující organizace
-
European Molecular Biology Laboratory
Uppsala universitet
Ethniko Kentro Erevnas Kai Technologikis
The main goal of MEDGENET consortium is to use synergies and existing expertise in EU leading institutions such as EMBL, Uppsala University and CERTH to reinforce the productivity and competitiveness of the CEITEC in the field of medical genomics and epigenomics. We propose clear strategy based on combination of unique complementary skills present in partner institutions that will transform CEITEC into a key leader in the field. ERA Chair who recently joint CEITEC already initiated the transformational change of the institute and TWINNING framework will further support sharing her international contacts with other CEITEC researchers. MEDGENET aims to create well-educated taskforce of biomedical researchers, who will notably contribute to the development of new genomics and bioinformatics tools and their application in clinical practice. Proposed project will enable to establish the best practices for performing innovative and high-quality biomedical research and to strengthen CEITEC´s competence to translate the research results into high value-added clinical applications. Stimulation of knowledge exchange, implementation of cutting edge technologies and mastery of modern genomics and bioinformatics methodologies will have a direct impact on the overall research and innovation potential of CEITEC and will increase its visibility in the international scientific community.
Publikace
Počet publikací: 52
2017
-
Chromothripsis is associated with altered gene expression in chronic lymphocytic leukemia
Rok: 2017, druh: Konferenční abstrakty
-
Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification
Haematologica/the hematology journal, rok: 2017, ročník: 102, vydání: 6, DOI
-
Observational study in comorbid patients with CLL receiving first-line rituximab-bendamustine
Rok: 2017, druh: Konferenční abstrakty
-
Promoter methylation of ROR ligand WNTA associates with its expression in chronic lymphocytic leukemia
Rok: 2017, druh: Konferenční abstrakty
-
The complexity of BCR signaling in CLL and other B cell malignancies: from the basic science to clinical applications.
Rok: 2017, druh: Konferenční abstrakty
-
The urea biosensor based on luminescence of Eu(III) ternary complex of DO3A ligand
Monatshefte fur Chemie, rok: 2017, ročník: 148, vydání: 11, DOI
-
Tracking Low-Burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation
Rok: 2017, druh: Konferenční abstrakty
-
Transcriptome sequencing provides novel insights into the biology of chronic lymphocytic leukemia: Focus on major stereotyped subsets
Rok: 2017, druh: Konferenční abstrakty
2016
-
ATM gene mutations represent a hallmark of mantle cell lymphoma but do not impact patients survival.
Rok: 2016, druh: Konferenční abstrakty
-
ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: Enrichment in subset 2 is associated with markedly short telomeres
Haematologica, rok: 2016, ročník: 101, vydání: 9, DOI